目前和新生物标志物在心脏性休克中
Victor Galusko1, Florian A Wenzl2,3,4,5, Christophe Vandenbriele1,6
1Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
European journal of heart failure
|January 17, 2025
概括
新的生物标志物可以预测和早期检测心脏性休克 (CS),指导治疗和改善结果. 追踪这些标志物有助于管理CS患者并预测生存率,为这种高死亡率的疾病提供希望.
科学领域:
- 心脏病学 心脏病学
- 生物标志物研究 生物标志物研究
- 关键护理医学 关键护理医学
背景情况:
- 心脏性休克 (CS) 具有高的住院死亡率 (30-50%),结果停滞不前.
- 晚期诊断和治疗启动是关键的挑战,导致不可逆转的血液动力学妥协.
- 有效的管理需要早期检测,预后和治疗干预的指导.
研究的目的:
- 审查当前和新型生物标志物用于预测,检测和评估CS的预后.
- 突出生物标志物的作用,指导管理和预测CS患者的结果.
- 探索生物标志物的时间变化如何为治疗策略提供信息,包括机械循环支持.
主要方法:
- 对心脏性休克生物标志物的现有文献进行批判性审查.
- 对超越乳酸等常规参数的新生物标志物的分析.
- 对反映系统性炎症,心肌抑郁和器官低 perfusion 的生物标志物的评估.
主要成果:
- 新型生物标志物,如上腺素和二基酶3,在预测CS发育和死亡率方面表现有前途.
- 像中白素-6和血管蛋白2这样的生物标志物表明与CS进展相关的全身炎症.
- 某些生物标志物信号末端器官的低输液,可能指导向治疗和确定治疗点.
结论:
- 生物标志物对于心脏性休克的早期预测,检测和预后至关重要.
- 时间生物标志物分析可以指导治疗干预,并预测患者的结果.
- 未来的生物标志物研究有可能优化高风险CS患者的管理.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
96
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
96
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
55
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
55
01:24Blood Pressure Imbalances and Circulatory Shock
743
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
743
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
378
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378